Patents by Inventor Andreas Pfeifer

Andreas Pfeifer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10066010
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 4, 2018
    Assignees: AC IMMUNE S.A., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • Patent number: 9829016
    Abstract: The invention relates to a flow conditioner for conditioning a fluid flow comprising a pipe having a constriction with a reduced pipe cross-section, at least one ring-shaped element arranged inside the pipe which has an outer diameter which is smaller than the inner diameter of the pipe in the axial region of the pipe in which the at least one ring-shaped element is arranged, and having an areal web whose surface normal is not in parallel with the pipe axis. The invention further relates to a throughflow measurement system for measuring a fluid throughflow through a pipe having a measurement device and a flow conditioner in accordance with the invention arranged upstream of the measurement device.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: November 28, 2017
    Assignee: SICK ENGINEERING GMBH
    Inventors: Andreas Gurr, Gerry Schroter, Andreas Pfeifer
  • Patent number: 9701660
    Abstract: The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: July 11, 2017
    Assignee: AC Immune S.A.
    Inventors: Heiko Kroth, Wolfgang Froestl, Andrea Pfeifer, Andreas Muhs
  • Patent number: 9687447
    Abstract: The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 27, 2017
    Assignee: AC Immune S.A.
    Inventors: Pedro Reis, David Hickman, Maria Pihlgren Bosch, Andreas Muhs, Andrea Pfeifer
  • Patent number: 9657091
    Abstract: The present invention provides methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to humanized antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 23, 2017
    Assignees: AC Immune S.A., Katholieke Universiteit Leuven
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • Publication number: 20170137502
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Application
    Filed: October 28, 2016
    Publication date: May 18, 2017
    Applicants: AC IMMUNE S.A., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • Patent number: 9598485
    Abstract: The present invention relates to anti-Tau antibodies, such as antibodies that bind to a phosphorylated epitope on human Tau protein with high specificity and/or affinity, and methods of using the same.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 21, 2017
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Gai Ayalon, Danielle Marie Di Cara, Isidro Hotzel, Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson
  • Patent number: 9585956
    Abstract: The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: March 7, 2017
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Patent number: 9540434
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 10, 2017
    Assignees: AC IMMUNE S.A., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • Publication number: 20160304590
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Application
    Filed: February 17, 2016
    Publication date: October 20, 2016
    Inventors: Andrea Pfeifer, Andreas Muhs, Fred Van Leuven, Maria Pihlgren, Oskar Adolfsson
  • Publication number: 20160272699
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: October 28, 2015
    Publication date: September 22, 2016
    Applicants: GENENTECH, INC., AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20160244514
    Abstract: The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 25, 2016
    Applicants: Genentech, Inc., AC Immune S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Patent number: 9403902
    Abstract: The present invention provides methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of amyloid-beta proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly those ocular diseases associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: August 2, 2016
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20160215048
    Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications.
    Type: Application
    Filed: September 5, 2014
    Publication date: July 28, 2016
    Inventors: Andrea PFEIFER, Greg DEL VAL
  • Publication number: 20160168234
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: July 20, 2015
    Publication date: June 16, 2016
    Applicants: GENENTECH, INC., AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Patent number: 9304138
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: April 5, 2016
    Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN, AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Andreas Muhs, Fred Van Leuven, Maria Pihlgren, Oskar Adolfsson
  • Publication number: 20160024193
    Abstract: The present invention relates to anti-Tau antibodies, such as antibodies that bind to a phosphorylated epitope on human Tau protein with high specificity and/or affinity, and methods of using the same.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: Gai Ayalon, Danielle Marie Di Cara, Isidro Hotzel, Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson
  • Publication number: 20160000910
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Application
    Filed: September 22, 2015
    Publication date: January 7, 2016
    Applicants: GENENTECH, INC., AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Patent number: 9221900
    Abstract: The present invention is related to safe and functional antibodies for the therapeutic and diagnostic use in the treatment of an amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: December 29, 2015
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Andreas Muhs, Oskar Adolfsson, Ryan J. Watts
  • Patent number: 9175094
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: November 3, 2015
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts